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Purpose: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based 
chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. 
Materials and Methods: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 
2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer 
specimens using eleven chemotherapeutic agents – etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, 
docetaxel, paclitaxel, methotraxate, and cisplatin – for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell 
death rate, and the chemosensitivity index. 
Results: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. 
Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemothera-
peutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more 
active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The 
lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxoru-
bicin, epirubicin, and mitomycin.
Conclusions: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of 
ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.
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Introduction 
Gastric cancer is the fourth leading cause of cancer death 
worldwide.(1) Gastric cancer is the most prevalent cancer in Korea 
and the treatment of gastric cancer patients accounts for the highest 
percentage of the national health expenditure, 19.1% of all cancer-
related health insurance payments.(2) Even after curative resection, 
advanced gastric cancer patients are given postoperative chemo-
therapy due to the high risk of recurrence because by adding che-
motherapy we may expect better patient survival than with surgery 
alone.(3-6) 
For gastric cancer, many chemotherapeutic agents are used. 
However, the chemotherapeutic effect of these drugs on gastric 
cancer is variable. Furthermore, neither a uniformly effective nor 
a standard chemotherapeutic regimen for gastric cancer has been 
clearly established. In efforts to improve the response rate to che-
motherapy, in vitro chemosensitivity tests have been employed to 
select the optimal chemotherapeutic agents for individual patients. 
Recently, adenosine-triphosphate based chemotherapy response 
assay (ATP-CRA) has demonstrated promising results in various 
types of cancers, such as melanoma, lung cancer, breast cancer, 
colorectal cancer and ovarian cancer.(7-11) Yet, little is known 
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about the applicability and reliability of ATP-CRA as an in vitro 
chemosensitivity test in gastric cancer. The purpose of this study 
was to investigate the reliability and the clinical applicability of 
ATP-CRA as a method of in vitro chemosensitivity in patients 
with gastric cancer.
Materials and Methods 
From February 2007 to January 2010, 243 patients who were 
preoperatively or intraoperatively diagnosed with advanced gastric 
cancer, stage II or greater, including one remnant gastric cancer at 
the Yonsei University College of Medicine, Severance Hospital were 
enrolled for the study. All patients agreed to the chemosensitivity 
test of their resected tumors and gave informed consent. We ex-
cluded patients who had received neo-adjuvant chemotherapy or 
were concurrently diagnosed with malignancies of another site. All 
the data on patients’ characteristics and pathologic features of the 
resected tumors were collected by retrospective review of medical 
records. 
ATP-CRA was performed as described elsewhere.(8,10) All tis-
sue specimens were obtained after surgical resection. Immediately 
after the surgical resection of a tumor, the specimen was sent to a 
pathology laboratory and a pathologist confirmed the tumor tissue. 
Then, a 0.5 cubic centimeter piece of the cancer tissue was col-
lected. The tissue specimens were stored in HBSS (GIBCO BRL, 
Rockville, MD, USA), containing 100 IU/ml penicillin (Sigma, St 
Louis, MO, USA), 100 μg/ml streptomycin (Sigma, St Louis, Mo, 
USA), 100 μg/ml gentamicin (GIBCO BRL, Rockville, MD, USA), 
2.5 μg/ml amphotericin B (GIBCO BRL, Rockville, MD, USA) and 
5% fetal bovine serum (FBS; GIBCO BRL, Rockville, MD, USA) 
and promptly transported to the laboratory. These tissue specimens 
underwent initial washing with 70% ethanol before being quantified 
and minced to a size less than 1 mm mechanical disaggregation. 
Then, for enzymatic disaggregation, they were incubated at 37oC 
with 5% CO2 for 12 to 16 hours with extracellular matrix degrad-
ing enzymes such as dispase (Sigma, St Louis, Mo, USA), pronase 
(Sigma, St Louis, Mo, USA) and DNase (Sigma, St Louis, Mo, 
USA). Cells were harvested using a cell strainer (BD Falcon, Bed-
ford, MA, USA). To remove red blood cells, normal cells, and ex-
cess debris, the cell suspensions were subjected to Ficoll-Hypaque 
(1077-1, Sigma, St Louis, Mo, USA) gradient centrifugation at 400 
g for 15 min and anti-CD45 antibody conjugated magnetic beads 
(Miltenyi Biotech, Auburn, CA, USA). Trypan blue exclusion test 
was used to determine the viability of isolated cells. 
After dilution of the separated tumor cells to 2,000~20,000 vi-
able cells/100 μl using IMDM (GIBCO BRL, Rockville, MD, USA), 
including 10% FBS, they were seeded in triplicate to a 96-well 
ultra low attachment microplate (Costar, Cambridge, MA, USA), 
which restricts the growth of normal cells. In the treated groups, 
100 μl of chemotherapeutic agents were added to the seeded cells; 
while in the untreated control groups, 100 μl of IMDM without 
chemotherapeutic agents was added to 3~6 wells of the microplate. 
The test drug concentrations were determined based on the peak 
plasma concentrations according to previous reports and prelimi-
nary training set experiments: etoposide (3.57 μg/ml), doxorubicin 
(1.5 μg/ml), epirubicin (1.2 μg/ml), mitomycin (0.2 μg/ml), 5-FU 
(10 μg/ml), oxaliplatin (2.9 μg/ml), irinotecan (4.7 μg/ml), docetaxel 
(3.7 μg/ml), paclitaxel (8.5 μg/ml), MTX (0.37 μg/ml) and cisplatin 
(2.5 μg/ml).(8,12,13) Three dilutions (0.2-, 1-, and 5-fold) of the 
test drug concentration were used in triplicate whenever sufficient 
number of cancer cell were available. For the purpose of quality 
control, a negative control group of 3~6 wells of seeding medium 
without cells and two positive control groups of 3 wells that con-
tained the minimal (105 pg ATP) and the median (280 pg ATP) 
amounts of ATP, as measured in 1,000 harvested tumor cells were 
included in the culture plate, respectively. The microplate was cul-
tured for 48 hours at 37oC in 5% CO2 with concomitant exposure 
to drugs. Then, the cells were lysed and the ATP content of each 
well were measured using the luciferin-luciferase system (Roche, 
Mannheim, Germany), followed by flash type luminescence mea-
surements on a Victor 3 multi-label counter (PerkinElmer Boston, 
MA, USA). 
Each of the cancer cell death rate (CDR) with luminscence val-
ues were calculated by the following formula.
A chemosensitivity index (CI) is calculated as the sum of the 
percentage inhibition at each concentration tested (CI=300-sum 
%Inhibition at 0.2-, 1-, and 5-fold of test drug concentration). The 
higher the value of CI, the greater the resistance to an anti-cancer 
drug. For every experiment, we calculated the intra assay mean co-
efficient of variation for quality control. For the calculation of coef-
ficient of variation value, the luminescence values of each specimen 
were measured 3 times. 
The chemosensitivity test of the ATP-CRA was considered a 
failure when the intra assay mean coefficient of variation for trip-
licate ATP measurements resulted in any value of over 30 or those 
CDR (%)=(1- Mean luminescence in treated cells )×100Mean luminescence in untreated control
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of the untreated control group which had a measurement less than 
105 pg ATP that of the positive control group. When inadequate 
numbers of cells were harvested or cell culture failed due to micro-
organism contamination, the test was also regarded as failure. 
1. Statistical analysis 
All statistical analyses were performed using the “Statistical 
Package for Social Science (SPSS)” version 18.0 for windows (SPSS 
Inc., Chicago, IL, USA). The difference of the chemosensitivity in-
dex between the early and the advanced gastric cancer groups, the 
serosa involved and the serosa non-involved groups, and the lymph 
node negative and the lymph node positive groups were compared 
using the Student t-test. A P-value＜0.05 was considered statisti-
cally significant.
Results
1. Clinicopathologic characteristics
Of the 243 patients, 4 of the patients were excluded from the 
study due to failure in the chemosensitivity test. The clinicopatho-
logic features those 239 patients are presented in Table 1. Of the 
239 patients, 168 were men and 71 were women. The mean age of 
239 patients was 59.0 years (range, 22~85 years). The distribution of 
the TNM stage according to the 7th AJCC classification included 
8 Stage IA (3.3%), 6 Stage IB (2.5%), 18 Stage IIA (7.5%), 43 Stage 
IIB (18.0%), 35 Stage IIIA (14.6%), 44 Stage IIIB (18.4% ), 63 Stage 
IIIC (26.4%), and 22 Stage IV (9.2%). 
2. In vitro chemosensitivity test results
Of the 243 patients who underwent gastrectomy, 4 cases failed 
the chemosensitivity test. Test failure rate was 1.6 % (4/243) and 
the reasons of the failure were as follows. Two tumor specimens 
showed lower measured values of the untreated control lower than 
those of the positive control group (105 pg ATP). These results 
were due to insufficient amount of viable cells or unacceptable vi-
abilities of tumor cells. A microorganism contamination was ob-
served in one specimen, and the other specimen did not yield any 
viable tumor cells. The mean coefficient of variation for triplicate 
ATP assay was 6.5±2.0% (range, 1.9~17.9%). Although ATP-
CRA results were obtained in 239 specimens, not all ATP-CRA 
produced complete results for all chemotherapeutic agents. More-
over, CIs for all the chemotherapeutic drugs were calculated in 160 
specimens (66.9%). 
The cytotoxic effect for test drug concentrations of the che-
Table 1. Clinicopathologic features of the patients
Characteristics No. of patients(N=239) %
Sex Male 168 70.3 
Female 71 29.7 
Age Mean 59
Range 22~85
Tumor location Upper 44 18.4 
Middle 44 18.4 
Lower 148 62.0 
Whole 2  0.8 
Anastomosis site 1  0.4 
T stage T1 11  4.6  
T2 21  8.8 
T3 63 26.4 
T4 144 60.3 
N stage N0 51 21.3 
N1 42 17.6 
N2 47 19.7 
N3 99 41.4 
M stage M0 217 90.8 
M1 22  9.2 
Stage Stage IA 8  3.3 
Stage IB 6  2.5 
Stage IIA 18  7.5 
Stage IIB 43 18.0 
Stage IIIA 35 14.6 
Stage IIIB 44 18.4 
Stage IIIC 63 26.4 
Stage IV 22  9.2 
Lauren Intestinal 111 46.4 
Classifi cation Diff use 115 48.1 
Mixed 8  3.3 
Unknown 5  2.1 
Lymphatic Yes 154 64.4 
  invasion No 84 35.6 
Unknown 1  0.4 
Vascular Yes 153 64.0 
  invasion No 85 35.6 
Unknown 1  0.4 
Neural Yes 160 66.9 
  invasion No 78 32.6 
Unknown 1  0.4 
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motherapeutic agents on cell death rate ranged from 0 to 92.2% 
(Table 2). The highest cancer cell death rate was demonstrated in 
cells treated with etoposide (35.9%), followed by 5-FU (34.9%), 
and mitomycin (32.8%). The agents which resulted in a wide range 
of cell death rates were paclitaxel (0~92.2%), docetaxel (0~91.2%), 
etoposide (0~87.5%). MTX showed the least cytotoxic effect (16.6%) 
and the narrowest range (0~62.7%). 
Table 3 shows each CI which indicates chemosensitivity of anti-
cancer drug calculated by the formula described in the Method 
section. The values of CI were heterogeneous among specimens. 
Table 4. Comparison of cell death rate at 1- fold test drug concentration
Serosa (-) Serosa (+) P-value LNI (-) LNI (+) P-value
Etoposide 36.1±20.9 30.9±22.6 0.442 40.6±23.1 34.6±20.2 0.069
Doxorubicin 25.1±19.0 22.2±13.9 0.635 30.2±20.3 23.5±18.1 0.024
Epirubicin 23.2±18.3 21.3±13.6 0.749 27.6±19.76 21.9±17.5 0.049
Mitomycin 32.8±20.3 33.1±19.9 0.967 38.1±22.2 31.4±19.5 0.036
5-Fluorouracil 34.8±14.7 37.6±14.1 0.548 36.8±16.9 34.4±14.1 0.306
Oxaliplatin 32.4±18.4 39.1±16.4 0.260 35.8±20.1 31.8±17.8 0.166
Irinotecan 30.4±16.9 32.7±13.0 0.669 29.5±15.9 30.8±17.0 0.637
Docetaxel 26.4±19.1 24.1±12.9 0.708 25.0±17.9 26.6±19.1 0.595
Paclitaxel 25.4±19.5 24.7±22.0 0.908 27.4±20.1 24.8±19.4 0.404
Methotrexate 16.4±12.2 21.3±11.4 0.207 16.4±11.8 16.6±12.3 0.892
Cisplatin 219.3±187.2 274.1±121.2 0.360 27.6±20.4 22.5±18.1 0.083
LNI = lymph node involvement.
Table 2. Cell death rate at 1- fold test drug concentration
Etoposide Doxorubicin Epirubicin Mitomycin 5-FU Oxaliplatin Irinotecan Docetaxel Paclitaxel MTX Cisplatin
Tested No. 238.0 237.0 237.0 237.0 239.0 237.0 237.0 238.0 239.0 237.0 239.0
Mean   35.9   25.0   23.1   32.8   34.9   32.6 30.5 26.3 25.4 16.6 23.5
SD (%)   20.9   18.8   18.1   20.2   14.7   18.4 16.8 18.8 19.6 12.2 18.7
Median   33.4   21.3   19.1   31.4   34.9   31.1 30.7 22.4 21.4 16.7 21.1 
Range 0~87.5 0~78.5 0~78.6 0~80.6 0~76.5 0~83.4 0~80.1 0~91.2 0~92.2 0~62.7 0~84.6
5-FU = 5-fl uorouracil; MTX = methotrexate; SD = standard deviation. 
Table 3. Chemosensitivity index (CI)*
Etoposide Doxorubicin Epirubicin Mitomycin 5-FU Oxaliplatin Irinotecan Docetaxel Paclitaxel MTX Cisplatin
CI tested No. 160 161 161   16 161 161   61 161 161 161 161 
CI (mean) 167 201 207 189 182 186 194 174 173 221 212
CI (range) 50~265 76~300 98~300 79~187 64~280 52~300 84~300 65~300 57~282 99~300 67~300
1st rank No. 51 2 1 4  10 18 8 18 44 0 4
1st rank % 31.9 1.2 0.6 2.5 6.2 11.2 5.0 11.2 27.3 0.0 2.5
2nd rank No. 13 11 5 21 16 11 12 46 21 2 2
2nd rank % 8.1 6.8 3.1 13.1 9.9 6.8 7.5 28.6 13.0 1.2 1.2
1~2 rank No. 64 13 6 25 26 29 20 64 65 2 6
1~2 rank (%) 40.0 8.1 3.7 15.6 16.1 18.0 12.4 39.8 40.4 1.2 3.7
5-FU = 5-fluorouracil; MTX = methotrexate. *Chemosensitivity index (CI) = 300-sum%Inhibition at 0.2-, 1-, and 5-fold of test drug 
concentration).
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The most active chemotherapeutic agent was etoposide which most 
frequently had the highest (top-ranked) chemosensitivity, 31.9% 
(51/160) for the tested specimens. When we compared the cell 
death rates according to the pathologic characteristics, there was a 
significant difference in cell death rates according to lymph node 
metastasis. The lymph node negative group showed significantly 
higher cell death rates than the lymph node positive group in doxo-
rubicin, epirubicin, and mitomycin (P＜0.05, respectively) (Table 4). 
Discussion 
From the early 1980s, many different types of in vivo and in 
vitro chemosensitivity tests were developed. Many tests such as sub-
renal capsule assay, human tumor clonogenic assay (HTCA), thy-
midine incorporation assay (TIA), succinic dehydrogenase inhibition 
assay (SDI), methylthiazoletetrazolium (MTT) assay, histoculture 
drug response assay (HDRA) were investigated.(14-19) There were, 
however, limitations in their clinical use due to various problems; 
lengthy assay period, difficulty in primary culture, a requirement 
of large specimen for the assay, contamination of fibroblasts, the 
different action mechanism of anti-cancer drugs, and the use of 
extremely high concentration of anti-cancer agents.(19-23) On the 
contrary, the ATP-CRA has demonstrated many advantages over 
above mentioned chemosensitivity tests. The ATP-CRA can be 
performed with a very small amount of cancer tissue, effectively 
eliminates or suppresses normal cells from the tissue specimens, 
has a higher sensitivity for evaluating viable cells, and is more ac-
curate than previous chemosensitivity tests.(16) ATP-CRA has 
been explored in many types of cancer as a method of selecting 
chemotherapy regimens based on individual difference in a variety 
of anti-cancer drugs.(7-13) 
The concept of in vitro chemosensitivity test is that it may help 
to differentiate the response of individual cancer patients to che-
motherapeutic agents. ATP-CRA showed clinical benefit for assay-
guided chemotherapy in breast cancer and ovarian cancer.(9,11) 
However, no studies have conclusively shown that an in vitro che-
mosensitivity test can predict the chemotherapy response of an in-
dividual patient. So far, the use of an in vitro chemosensitivity assay 
for clinical practice is not recommended except in clinical trials.
(23) Unlike breast or ovarian cancer, the benefits of chemotherapy 
after gastrectomy for gastric cancer are not fully established; and 
even though, some phase III randomized prospective clinical trials 
have shown survival benefits of chemotherapy,(24-26) no standard 
chemotherapeutic regimen for gastric cancer can be recommended. 
Therefore, provided that an in vitro chemosensitivity assay could 
accurately predict the in vivo chemo-responsiveness of the patients, 
its application may be an ideal method of identifying the most ef-
fective patient specific chemotherapy agent. 
The study results using different methods of in vitro chemo-
sensitivity assay in gastric cancer inconsistent.(27,28) These con-
tradictory results may come from differences in the nature of each 
method, differences in chemotherapeutic agents, and the study 
design. In this study, the cell death rate for each chemotherapeutic 
drug showed wide ranges. This may represent heterogeneous re-
sponse of each cancer tissues to various anti-cancer agents. Thus, 
selecting proper drugs which can show effective chemotherapeutic 
effect is important. 
There were reports regarding ATP-CRA for gastric cancer pa-
tients with a small study sample size.(29,30) One is a study of the 
effectiveness of ATP-CRA guided chemotherapy for unresectable 
gastric cancer patients. Although they suggested potential benefits 
of ATP-CRA guided chemotherapy by demonstrating complete 
remission and long-term survival, they could not evaluate the 
methodological stability of ATP-CRA.(29) The other is a study 
similar to our study. However, Lee(30) showed only cell death rate 
at a specific concentration of chemotherapeutic agent. In his study, 
he did not show the chemosensitivity index which can be a baseline 
data for the clinical application of ATP-CRA. In our study, ATP-
CRA showed a low failure rate (1.6%) and a low intra assay mean 
coefficient of variation (6.5%) in a large study population. Thus, our 
study confirms that ATP-CRA is a stable and clinically applicable 
in vitro chemosensitivity assay suited for validation studies of assay-
guided chemotherapy for gastric cancer patients. This high success 
rate may be related to the rapid and exact sampling of the cancer 
tissue by the pathologist performed immediately after a surgical 
resection and the effective elimination of normal cells processing of 
the specimen with the ficoll gradient centrifugation and anti-CD45 
immunomagnetic separation.(8) Moreover, the chemo-response to 
certain anti-cancer drugs was related to the characteristics of the 
tumor. This further supports the pursuit of an individualized che-
motherapeutic approach in gastric cancer.
Our study has several limitations. A few of the anti-cancer 
agents which showed high cell death rates may be difficult to 
evaluate in practice since they are not included in clinically used 
regimens. In addition, since we studied the ATP-CRA only for 
single agents, the effect of combining anti-cancer drugs could not 
be investigated. Thus, we cannot estimate the interaction between 
the drugs and different pharmacokinetic effects of individual pa-
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tients. Nevertheless, our study provided the possibility of an in vitro 
detection of the chemotherapeutic agents with a potential for a 
high success rate. From these results, studies on survival benefits of 
various anti-cancer agents for gastric cancer based on ATP-CRA 
results and a prospective study comparing in vitro chemosensitivity 
assay-guided chemotherapy with empiric chemotherapy are war-
ranted. 
In conclusion, ATP-CRA is a stable and clinically applicable 
in vitro chemosensitivity test with a low failure rate. The clinical 
usefulness of ATP-CRA should be evaluated by prospective studies 
comparing regimen guided by ATP-CRA with the empirical regi-
men.
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